Evidence network for deaths_(OS)

2IMpassion-130 (all population), 2018 IMpassion-130 (PDL1>1%), 20182IMpassion-131 (PD-L1 > 1%), 2020 IMpassion-131 (all population), 20203KEYNOTE-355 (all population), 2020 KEYNOTE-355 (CPS>1), 2020 KEYNOTE-355 (CPS>10), 20202PAKT (all population), 2020 PAKT (PIK3CA/AKT1/PTEN-altered), 20201LOTUS, 20171BrighTNess (velaparib-P-C (arm A) vs paclitaxel alone (arm C)), 20182TORCHLIGHT, 2024 TORCHLIGHT PDL 1 positive population, 2024nab-paclitaxelpaclitaxelStandard of Care (SoC)nab-paclitaxel plus placeboatezolizumab plus nab-paclitaxelatezolizumab plus paclitaxelpembrolizumab plus SoCcapivasertib plus paclitaxelipatasertib plus paclitaxelveliparib plus paclitaxel plus carboplatinnab-paclitaxel plus toripalimabcamrelizumab alonedirect evidencenetwork meta-analysis
T vs. C nab-paclitaxelpaclitaxelStandard of Care (SoC)nab-paclitaxel plus placeboatezolizumab plus nab-paclitaxelatezolizumab plus paclitaxelpembrolizumab plus SoCcapivasertib plus paclitaxelipatasertib plus paclitaxelveliparib plus paclitaxel plus carboplatinnab-paclitaxel plus toripalimabcamrelizumab alone
nab-paclitaxel---NANANANANANANANANANANA
paclitaxelNA---NANANANANANANANANANA
Standard of Care (SoC)NANA---NANANANANANANANANA
nab-paclitaxel plus placeboNANANA---NANANANANANANANA
atezolizumab plus nab-paclitaxelNANANANA---NANANANANANANA
atezolizumab plus paclitaxelNANANANANA---NANANANANANA
pembrolizumab plus SoCNANANANANANA---NANANANANA
capivasertib plus paclitaxelNANANANANANANA---NANANANA
ipatasertib plus paclitaxelNANANANANANANANA---NANANA
veliparib plus paclitaxel plus carboplatinNANANANANANANANANA---NANA
nab-paclitaxel plus toripalimabNANANANANANANANANANA---NA
camrelizumab aloneNANANANANANANANANANANA---

pathologies: 269,60,143 - treatments: 661 result logic